GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Enterprise Value

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Enterprise Value : $183.15 Mil (As of May. 17, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Telomir Pharmaceuticals's Enterprise Value is $183.15 Mil. Telomir Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-12.86 Mil. Therefore, Telomir Pharmaceuticals's EV-to-EBIT ratio for today is -14.24.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Telomir Pharmaceuticals's Enterprise Value is $183.15 Mil. Telomir Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-12.86 Mil. Therefore, Telomir Pharmaceuticals's EV-to-EBITDA ratio for today is -14.24.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Telomir Pharmaceuticals's Enterprise Value is $183.15 Mil. Telomir Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Telomir Pharmaceuticals's EV-to-Revenue ratio for today is .


Telomir Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Telomir Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Enterprise Value Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Enterprise Value
- - -

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Telomir Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Telomir Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Enterprise Value falls into.



Telomir Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Telomir Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Telomir Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals  (NAS:TELO) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Telomir Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=183.145/-12.861
=-14.24

Telomir Pharmaceuticals's current Enterprise Value is $183.15 Mil.
Telomir Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.86 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Telomir Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=183.145/-12.861
=-14.24

Telomir Pharmaceuticals's current Enterprise Value is $183.15 Mil.
Telomir Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.86 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Telomir Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=183.145/0
=

Telomir Pharmaceuticals's current Enterprise Value is $183.15 Mil.
Telomir Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines